Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Mallinckrodt-Data

More Like This

PR Newswire associated0

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

PR Newswire associated0

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

PR Newswire associated0

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

Business Wire logo

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress

PR Newswire associated0

Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Business Wire logo

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025